Online inquiry

IVTScrip™ mRNA-Human ACSL3, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK9447MR)

This product GTTS-WK9447MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the ACSL3 protein. This product can be used in Monocyte-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001354158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 2181
UniProt ID O95573
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACSL3, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WK9447MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18047MR IVTScrip™ mRNA-Human AK2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AK2
GTTS-WK20522MR IVTScrip™ mRNA-Human Alkaline phosphatase, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Alkaline phosphatase
GTTS-WK19299MR IVTScrip™ mRNA-Human ALDH3A1, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALDH3A1
GTTS-WK11241MR IVTScrip™ mRNA-Human ACPP, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACPP
GTTS-WK1801MR IVTScrip™ mRNA-Human Intestinal Alkaline Phosphatase, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Intestinal Alkaline Phosphatase
GTTS-WK5410MR IVTScrip™ mRNA-Human MMP-13, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MMP-13
GTTS-WK13051MR IVTScrip™ mRNA-Human ACSM2A, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACSM2A
GTTS-WK6931MR IVTScrip™ mRNA-Human ZAP70, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZAP70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW